{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"107"},{"groupId":"OG001","value":"109"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"262"},{"groupId":"OG001","value":"263"}],"units":"Participants"}],"description":"Criteria for vital signs abnormalities: systolic blood pressure \\<80 millimeter of mercury (mmHg), \\>210 mmHg; diastolic blood pressure \\<40 mmHg, \\>130 mmHg; heart rate \\<40 beats per minute (bpm), \\>150 bpm; temperature \\<32 degree celsius, \\>40 degree celsius; weight \\>=10% increase from baseline, \\>=10% decrease from baseline. The number of participants with any vital sign abnormalities during On-treatment period are reported. On-Treatment was defined as values collected after the date of the first dose of test article until the last date of test article +28 days.","groups":[{"description":"Participants with Philadelphia chromosome-positive CML received bosutinib tablets at a dose of 400 mg, orally once daily in the core treatment phase of 12 months and continued the same treatment into the extension phase or followed up for safety for up to approximately 4 years, until the end of the study, treatment failure, unacceptable toxicity, death, or withdrawal of consent, whichever occurred first.","id":"OG000","title":"Bosutinib"},{"description":"Participants with Philadelphia chromosome-positive CML received imatinib tablets at a dose of 400 mg, orally once daily in the core treatment phase of 12 months and continued the same treatment into the extension phase or followed up for safety for up to approximately 4 years, until the end of the study, treatment failure, unacceptable toxicity, death, or withdrawal of consent, whichever occurred first.","id":"OG001","title":"Imatinib"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety population included all participants who received at least 1 dose of study medication with treatment assignments designated to actual study treatment received. Here, \"N\" signifies number of participants evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Baseline up to end of treatment (up to Month 60)","title":"Number of Participants With Vital Signs Abnormalities","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"Participants"}